All In Biotech

Drug Trial Radar · NCT02786485

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant

Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 2016

Primary completion

Dec 2018

Study completion Dec 2018

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, multicenter, open-label, non-randomized study of matched unrelated donor BPX-501 T cell infusion in adult subjects with hematological malignancies presenting with recurrent disease minimal residual disease (MRD) post-allogeneic transplant.

Conditions

  • Leukemia
  • Myelodysplastic Syndromes
  • Lymphomas
  • Multiple Myeloma
  • Other High-risk Hematological Malignancies

Interventions

  • rivogenlecleucelBiological

    T cells transduced with iCasp safety switch

  • RimiducidDrug

    administered to treat GVHD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: 30 days after last dose of study drug (BPX-501 and/or rimiducid)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.